Literature DB >> 19954823

The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: comparison of the PFA-100, multiplate electrical impedance aggregometry and verify now assays.

Mehmet Mustafa Can1, Ibrahim Halil Tanboğa, Erdem Türkyilmaz, Can Yucel Karabay, Taylan Akgun, Fatih Koca, Hacer Ceren Tokgoz, Nursen Keles, Alper Ozkan, Tahir Bezgin, Olcay Ozveren, Kenan Sonmez, Mustafa Sağlam, Nihal Ozdemir, Cihangir Kaymaz.   

Abstract

OBJECTIVES: Evaluation of aspirin (ASA) responsiveness with platelet function tests varies by the choice of blood mixture and functional test and cut off values for defining the the treatment used. Addition to that we also aimed to determine agreement between three tests and to research whether there is any necessity to measure baseline platelet activity.
METHODS: The study group comprised of 52 patients with multiple risk factors receiving primary prophylaxis of ASA (100 mg/day). For each patient inhibition of platelet aggregation with aspirin was determined using three different whole blood tests: Multiplate electrical impedance aggregometry, Verify Now Aspirin, and collagen-epinephrine closure time PFA-100. Platelet aggregation was assessed with multiplate electrical impedance aggregometry,and was defined as the area under curve (AUC,AUxmin). Maximal 6,4 microM collagen-induced AUC were used to quantify platelet aggregation due to ASA. The ASA response was defined as >30 % reduction in basal platelet aggregation with multiplate electrical impedance aggregometry. Collagen induced platelet aggregation at the Verify Now Aspirin assay quantitated the ASA-induced platelet inhibition as aspirin reaction units (ARU). According to manufacturer insert ARU>550 indicates aspirin resistance. ASA platelet function studies were assessed twice at baseline (pre-aspirin), and after 7 day(post-aspirin) were performed.
RESULTS: After ASA intake none of the patients was found aspirin resistant with PFA-100. (CEPI-CT (129+/-36 vs 289+/-18 ). None of the patients was found aspirin resistant with PFA-100. As>30 % reduction in basal platelet aggregation with multiplate electrical impedance aggregometry is selected all of the patients have been stratified as responders.(COL TEST 688+/-230 vs 169+/-131 AU) None of the patients with Verify Now Aspirin found resistance to ASA(594+/-62 vs 446+/-43).Prior to ASA intake 15 of all patients with VN(501+/-16) and 2 of all patients with multiplate electrical impedance aggregometry (223+/-40 AUC )aggregation levels below the cut off label before ingestion of ASA.None of the patients was above the cut off label with PFA -100 (129+/-36).
CONCLUSIONS: Verify Now ASA assay, multiplate electrical impedance aggregometry and PFA-100 seem to be reliable tests in reflecting ASA effect on platelets. Cut off labels for the defining the responsiveness given by manufacturer may show significant interindividual variability with Verify Now ASA assay and multiplate electrical impedance aggregometry, and these test may show platelet inhibition despite the absence of ASA intake. Consideration of the pretreatment values may eliminate the risk of overestimation in the assessment of platelet inhibition by ASA. (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19954823     DOI: 10.1016/j.thromres.2009.11.005

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

Review 1.  Antiplatelet treatment in essential hypertension: where do we stand?

Authors:  Eugenia Gkaliagkousi; Eleni Gavriilaki; Stella Douma
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

2.  Characterization of platelet dysfunction after trauma.

Authors:  Matthew E Kutcher; Brittney J Redick; Ryan C McCreery; Ian M Crane; Molly D Greenberg; Leslie M Cachola; Mary F Nelson; Mitchell Jay Cohen
Journal:  J Trauma Acute Care Surg       Date:  2012-07       Impact factor: 3.313

3.  Increased platelet reactivity is associated with circulating platelet-monocyte complexes and macrophages in human atherosclerotic plaques.

Authors:  Bert Rutten; Claudia Tersteeg; Joyce E P Vrijenhoek; Thijs C van Holten; Ellen H A M Elsenberg; Elske M Mak-Nienhuis; Gert Jan de Borst; J Wouter Jukema; Nico H J Pijls; Johannes Waltenberger; Anton Jan van Zonneveld; Frans L Moll; Elizabeth McClellan; Andrew Stubbs; Gerard Pasterkamp; Imo Hoefer; Philip G de Groot; Mark Roest
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

4.  Tanshinone IIA improves hypoxic ischemic encephalopathy through TLR‑4‑mediated NF‑κB signal pathway.

Authors:  Chengzhi Fang; Lili Xie; Chunmei Liu; Chunhua Fu; Wei Ye; Hong Liu; Binghong Zhang
Journal:  Mol Med Rep       Date:  2018-06-26       Impact factor: 2.952

5.  Associations Between PFA-Measured Aspirin Resistance, Platelet Count, Renal Function, and Angiotensin Receptor Blockers.

Authors:  Hung Yi Chen; Pesus Chou
Journal:  Clin Appl Thromb Hemost       Date:  2018-07-11       Impact factor: 2.389

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.